Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • P&G to acquire 51.8...

    P&G to acquire 51.8 percent stake in Merck in India for Rs 1,290 crore

    Written by Ruby Khatun Khatun Published On 2018-04-21T10:30:38+05:30  |  Updated On 21 April 2018 10:30 AM IST
    P&G to acquire 51.8 percent stake in Merck in India for Rs 1,290 crore

    New Delhi: Procter & Gamble (P&G) will acquire 51.80 percent stake for Rs 1,289.88 crore in India listed drug firm Merck Ltd as part of a global deal under which it is taking over German firm Merck KGaA’s international consumer health business.


    The global deal is for about 3.4 billion euro (Rs 27,677 crore) in cash. P&G will acquire Merck’s majority shareholding in Merck Ltd. (India) and make a mandatory tender offer to minority shareholders.


    In a regulatory filing, Merck Ltd said Procter & Gamble Overseas India B.V and The Procter & Gamble Company have launched an up to Rs 647.53 crore open offer to acquire up to 4,315,840 equity shares of Merck Ltd, constituting 26 percent stake from public shareholders.


    The open offer document said: “The acquirer (Procter & Gamble Overseas India B.V and The Procter & Gamble Company) has entered into a sale and purchase agreement…wherein it is proposed that the acquirer shall purchase from Emedia Export Company MBH, Merck Internationale Beteiligungen GmbH and Chemitra GmbH 8,599,224 equity shares…which constitutes 51.80 percent of the voting share capital.”


    It further said sale of the equity shares held by the sellers is proposed to be executed at a “price of up to Rs 1,500 per fully paid up equity share aggregating to up to Rs 1,289,88,36,000 total for all equity shares held by the sellers payable as Euro equivalent in cash”.


    The company also said under the open offer by P&G, up to 26 per cent of the fully diluted voting equity share capital will be acquired at a price of Rs 1,500.36 per share amounting to Rs 647.53 crore.


    On the impact of the global transaction in India, Merck Ltd said: “As part of the transaction, Merck and P&G have agreed to a number of manufacturing, supply and service agreements.”

    acquireequity sharesIndiainternational consumer health businessMerckminority shareholdersP&GProcter & Gamblestaketender offer
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok